No Data
No Data
Chengda Pharmaceutical: 2024 Annual Report
Chengda Pharmaceutical: 2024 Annual Report Summary
Chengda Pharmaceutical: Report for the first quarter of 2025
Chengda Pharmaceutical (301201.SZ) released its first-quarter performance, turning from profit to a loss of 1.4 million yuan.
Chengda Pharmaceutical (301201.SZ) released its first quarter report for 2025, with the company's revenue of 7630...
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Investor Optimism Abounds ChengDa Pharmaceuticals Co., Ltd. (SZSE:301201) But Growth Is Lacking